title: Rapid deterioration in a patient with primary aggressive cutaneous epidermotropic CD8+ cytotoxic T-cell ('Berti') lymphoma after administration of adalimumab.
authors.affiliation: School of Medicine, Medical University of South Carolina, Charleston, South Carolina.
authors.forename: Sarah M
authors.initials: SM
authors.lastname: Jacks
authors.affiliation: Department of Dermatology and Dermatologic Surgery, Medical University of South Carolina, Charleston, South Carolina. Electronic address: brent.taylor@post.harvard.edu.
authors.forename: Brent R
authors.initials: BR
authors.lastname: Taylor
authors.affiliation: Athens Regional Pathology Associates, Georgia.
authors.forename: Raford P
authors.initials: RP
authors.lastname: Rogers
authors.affiliation: Department of Pathology and Laboratory Medicine, Medical University of South Carolina, Charleston, South Carolina.
authors.forename: Jonathan S
authors.initials: JS
authors.lastname: Ralston
authors.affiliation: Department of Pathology and Laboratory Medicine, Medical University of South Carolina, Charleston, South Carolina.
authors.forename: John S
authors.initials: JS
authors.lastname: Metcalf
authors.affiliation: Department of Pathology and Laboratory Medicine, Medical University of South Carolina, Charleston, South Carolina.
authors.forename: John
authors.initials: J
authors.lastname: Lazarchick
mesh_terms: D000068879:Adalimumab; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects*; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D016410:Lymphoma, T-Cell, Cutaneous / Q000175:diagnosis* / Q000276:immunology / Q000473:pathology; D011565:Psoriasis / Q000175:diagnosis / Q000188:drug therapy; D012878:Skin Neoplasms / Q000175:diagnosis* / Q000276:immunology / Q000473:pathology; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology
chemical_list: D000893:Anti-Inflammatory Agents; D061067:Antibodies, Monoclonal, Humanized; D000068879:Adalimumab